ANDA 211146, held by Zydus Pharms. Vortioxetine Hydrobromide.
As of Nov 16, 2026, ANDA 211146 (Vortioxetine Hydrobromide), held by Zydus Pharms, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 2, 2024 | Original application | Tentative approval |
| Vortioxetine HydrobromideEQ 5MG BASE · tablet;oral | Vortioxetine Hydrobromide | Discontinued |
| Vortioxetine HydrobromideEQ 10MG BASE · tablet;oral | Vortioxetine Hydrobromide | Discontinued |
| Vortioxetine HydrobromideEQ 20MG BASE · tablet;oral | Vortioxetine Hydrobromide | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters